Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of Shares

CEO, CFO, Managing Director of Uniqure Nv (30-Year Financial, Insider Trades) Matthew C Kapusta (insider trades) sold 8,000 shares of QURE on 07/17/2019 at an average price of $71.45 a share. The total sale was $571,600.

uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. uniQure NV has a market cap of $2.79 billion; its shares were traded at around $73.91 with and P/S ratio of 305.43. uniQure NV had annual average EBITDA growth of 1.60% over the past five years. GuruFocus has detected 2 severe warning signs with uniQure NV. .

CEO Recent Trades:

  • CEO, CFO, Managing Director Matthew C Kapusta sold 8,000 shares of QURE stock on 07/17/2019 at the average price of $71.45. The price of the stock has increased by 3.44% since.

CFO Recent Trades:

  • CEO, CFO, Managing Director Matthew C Kapusta sold 8,000 shares of QURE stock on 07/17/2019 at the average price of $71.45. The price of the stock has increased by 3.44% since.

For the complete insider trading history of QURE, click here

.